Antibacterial Resistance Leadership Group: Open for business

20Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

Abstract

Funded by the National Institute of Allergy and Infectious Diseases, the Antibacterial Resistance Leadership Group (ARLG) is tasked with developing a clinical research agenda and conducting clinical studies to address the growing public health threat of antibacterial resistance. The ARLG has identified 4 high-priority areas of research: infections caused by gram-negative bacteria, infections caused by gram-positive bacteria, antimicrobial stewardship and infection prevention, and diagnostics. The ARLG will be accepting proposals from the scientific community for clinical research that addresses 1 or more of these high-priority areas. These studies should have the potential to transform medical practice and be unlikely to occur without ARLG support. The purpose of this article is to make interested parties aware of clinical research opportunities made available by ARLG and to encourage submission of clinical research proposals that address the problem of antibacterial resistance. © The Author 2014.

Cite

CITATION STYLE

APA

Chambers, H. F., Bartlett, J. G., Bonomo, R. A., Chiou, C., Cosgrove, S. E., Cross, H. R., … Fowler, V. G. (2014). Antibacterial Resistance Leadership Group: Open for business. Clinical Infectious Diseases, 58(11), 1571–1576. https://doi.org/10.1093/cid/ciu132

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free